Received Feb 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 2553X | — |
patient received a first dose of Twinrix in Aug 7th 2024 and second dose was given today Feb 7th 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 72-year-old female patient who received HAB (Twinrix) (batch number 2553X, expiry date 25-SEP-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 07-AUG-2024, batch number 2553X, expiry date 25-SEP-2026). On 07-FEB-2025, the patient received the 2nd dose of Twinrix. On 07-FEB-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: patient received a first dose of Twinrix in Aug 7th 2024 and second dose was given today Feb 7th 2025). The outcome of the drug dose administration interval too long was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-FEB-2025 A pharmacist reported that a patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccination schedule The pharmacist asked if series should be re started